Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 9/20 | 0.97 |
| ▸ | MAOA | P21397 | 8/20 | 0.97 |
| ▸ | ACHE | P22303 | 7/20 | 0.97 |
| ▸ | BCHE | P06276 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HTR6 | P50406 | 1/20 | 0.97 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilect SCHEMBL5444067 | 1.00 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL5449858 | 1.00 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL332967 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL29605291 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL12787613 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL74699 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL333333 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL828802 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2028892 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116211840-A | Pharmaceutical composition containing rasagiline or pharmaceutically acceptable salt thereof and preparation method thereof | 江苏先声药业有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115838333-A | Synthetic method of rasagiline mesylate | 江苏苏中药业研究院有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-2328861-A2 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | Synthon BV (NL) | 2011-06-08 | — | — | EP | claimed |
| WO-2011012140-A2 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | SYNTHON BV (NL) | 2011-02-03 | — | — | WO | claimed |
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-02-18 | — | — | US | claimed |
| WO-2010007181-A2 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-01-21 | — | — | WO | claimed |
| US-20100010098-A1 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | SYNTHON BV (NL) | 2010-01-14 | — | — | US | claimed |
| CN-118141772-B | Ropinirole Luo Jia hydrochloride sulfonic acid rasagiline compound orally disintegrating controlled release tablet and preparation method thereof | 四川鲁徽制药有限责任公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118141772-A | Ropinirole Luo Jia hydrochloride sulfonic acid rasagiline compound orally disintegrating controlled release tablet and preparation method thereof | 四川鲁徽制药有限责任公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-116082131-B | Method for synthesizing 1-indanone compound by one-pot method | 苏州华道生物药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116211840-A | Pharmaceutical composition containing rasagiline or pharmaceutically acceptable salt thereof and preparation method thereof | 江苏先声药业有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116082131-A | Method for synthesizing 1-indanone compound by one-pot method | 苏州华道生物药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115838333-A | Synthetic method of rasagiline mesylate | 江苏苏中药业研究院有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-5457133-A | Treating Parkinson's disease, memory disorders, Alzheimer's disease, depression and hyperactive syndrome | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-10-10 | — | — | US | disclosed |
| US-5453446-A | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-09-26 | — | — | US | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995011016-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-04-27 | — | — | WO | disclosed |
| US-5387612-A | Administering title compound or salt; memory disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-02-07 | — | — | US | disclosed |
| EP-0436492-B1 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | TEVA PHARMA (IL) | 1994-06-08 | — | — | EP | disclosed |
| EP-0436492-A2 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | Teva Pharmaceutical Industries Limited (IL) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | RAB35, RAB7A, RAB10 | MAOB 2254/4885MAOA 1787/4885ACHE 1630/4885 |
| US-20100010098-A1 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | PARK7, RAB27A, SNCA | MAOB 407/4885MAOA 196/4885ACHE 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.